首页> 外文学位 >Release behavior of alkyl-p-aminobenzoate ester-PVP solid dispersions.
【24h】

Release behavior of alkyl-p-aminobenzoate ester-PVP solid dispersions.

机译:烷基对氨基苯甲酸酯-PVP固体分散体的释放行为。

获取原文
获取原文并翻译 | 示例

摘要

Solid polymer-drug dispersions are used to prepare and stabilize amorphous forms of poorly soluble drugs as a means of improving drug solubility, dissolution and bioavailability. Despite many reports on this subject, solid dispersion dissolution mechanisms have not been well understood. An early study was reported by Simonelli, Mehta and Higuchi (SMH) in 1969 and has served as a model for dispersion dissolution behavior. These authors proposed a dissolution model (SMH) which gave good agreement between their experimental results and model predictions for one drug and one type of PVP.;Few researchers have applied this traditional approach (SMH) in a systematic fashion to solid dispersion systems. One difficulty is obtaining parameters needed for predictions such as polymer diffusion coefficient, diffusion layer thickness or other pertinent parameters. In this work, a general model has been developed based on the concepts in the traditional approach (SMH) and simulations with this model were performed to show how dispersion dissolution rates change with system variables. Such simulations showed underestimation of dissolution rates resulted when compounds had low solubility.;In this work, solid dispersion dissolution behavior was studied systematically with a homologous compound series (alkyl-p-aminobenzoate esters, or PABA esters) and three polyvinylpyrrolidone (PVP) molecular weights (K15, K30 and K90). The PABA esters with varying solubility used in this study were methyl PABA (MePABA), ethyl PABA (EtPABA), propyl PABA (PrPABA) and butyl PABA (BuPABA). Six solid dispersions for each PABA ester and PVP (weight ratios of PVP:PABA ester 20:1, 10:1, 6:1, 3:1, 4:1 and 2:1) were prepared by a solvent evaporation method. Solid dispersions were obtained and their amorphous character confirmed by powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC). Intrinsic dissolution rates for these dispersions were obtained in water with a rotating disc dissolution system. Both dissolution rate of drug (PABA ester) and carrier (PVP) were measured to obtain more information on which to evaluate the release behavior. Measuring the dissolution of the polymer (dispersion agent) and drug is unique in this work and has not been done in most other reported studies.;For the more soluble PABA esters (i.e., MePABA, EtPABA and PrPABA), as drug loading increased, PABA ester dissolution rates first increased and then decreased to that of the pure drug for PVP K15 and K30 dispersions. For K90 systems, drug dissolution rates were below pure drug rates and increased steadily as drug loading increased, eventually reaching that of the pure drug. On the other hand, PVP dissolution rates decreased constantly as drug content increased for all three PVP grades. However, the decrease in polymer dissolution was more pronounced for the lower molecular weight PVPs (K15 and K30) than the higher molecular weight PVP (K90). Comparison of drug and polymer dissolution behavior indicated that congruent release of both components occurred when drug loading was low (<15%). As drug loading increased, more deviation from congruent release behavior was observed. For BuPABA, the least soluble PABA ester, precipitated BuPABA solid accumulated on the disc surface during dissolution.;PABA ester relative dissolution rates were calculated and compared with the predictions from the developed general model (based on assumptions in the traditional approach). Such predictions correlated well with experimental results at high drug loadings (i.e., >25%) but at low drug loadings (i.e., <25%) there was inconsistent correlation between experimental and predicted results. A new model was developed in which dispersion systems were generally classified into two regions: a carrier-controlled region and a drug-controlled region. Congruent release was predominated in the carrier-control region and pure drug release occurred in the drug-controlled region. The results showed the new model offered better agreement with experimental results.
机译:固体聚合物-药物分散体用于制备和稳定难溶性药物的无定形形式,作为改善药物溶解度,溶解度和生物利用度的手段。尽管有许多关于该主题的报道,但是对固体分散体的溶解机理还没有很好的理解。 Simonelli,Mehta和Higuchi(SMH)于1969年报告了一项早期研究,该研究已成为分散体溶解行为的模型。这些作者提出了一种溶出模型(SMH),该模型在他们的实验结果与一种药物和一种PVP类型的模型预测之间取得了很好的一致性。很少有研究者以系统的方式将这种传统方法(SMH)应用于固体分散系统。一个困难是获得预测所需的参数,例如聚合物扩散系数,扩散层厚度或其他相关参数。在这项工作中,已基于传统方法(SMH)中的概念开发了一个通用模型,并对该模型进行了仿真,以显示分散体溶解速率如何随系统变量而变化。这样的模拟表明,当化合物具有低溶解度时,溶解速率会被低估。;在这项工作中,系统地研究了同源化合物系列(烷基对氨基苯甲酸酯或PABA酯)和三个聚乙烯吡咯烷酮(PVP)分子对固体分散体的溶解行为。重量(K15,K30和K90)。在这项研究中使用的具有不同溶解度的PABA酯是甲基PABA(MePABA),乙基PABA(EtPABA),丙基PABA(PrPABA)和丁基PABA(BuPABA)。通过溶剂蒸发法制备每种PABA酯和PVP的六种固体分散体(PVP∶PABA酯的重量比为20∶1、10∶1、6∶1、3∶1、4∶1和2∶1)。获得了固体分散体,并通过粉末X射线衍射(PXRD)和差示扫描量热法(DSC)确认了它们的无定形特性。使用旋转盘溶解系统在水中获得这些分散体的固有溶解速率。测量药物(PABA酯)和载体(PVP)的溶解速率,以获得更多有关评估释放行为的信息。测量聚合物(分散剂)和药物的溶解度在这项工作中是独特的,在大多数其他已报道的研究中还没有完成。对于PVP K15和K30分散体,PABA酯的溶解速率首先增加,然后下降至纯药物。对于K90系统,药物溶解速率低于纯药物速率,并随着载药量的增加而稳定地增加,最终达到纯药物的溶解量。另一方面,随着三种PVP等级药物含量的增加,PVP溶出度不断降低。但是,与较高分子量的PVP(K90)相比,较低分子量的PVP(K15和K30)聚合物溶解的降低更为明显。药物和聚合物溶解行为的比较表明,当载药量较低(<15%)时,两种成分均会完全释放。随着载药量的增加,观察到与同等释放行为的更多偏差。对于BuPABA,是最不溶的PABA酯,在溶解过程中沉淀的BuPABA固体积聚在椎间盘表面上;计算了PABA酯的相对溶解速率,并将其与已开发的通用模型的预测值进行比较(基于传统方法的假设)。这样的预测与高载药量(即> 25%)下的实验结果很好地相关,但是在低载药量(即<25%)下,实验结果和预测结果之间的相关性不一致。开发了一种新模型,其中分散系统通常分为两个区域:载体控制区域和药物控制区域。一致的释放在载体控制区占主导,纯药物释放发生在药物控制区。结果表明,新模型与实验结果吻合较好。

著录项

  • 作者

    Wu, Yi.;

  • 作者单位

    The University of Iowa.;

  • 授予单位 The University of Iowa.;
  • 学科 Pharmaceutical sciences.
  • 学位 Ph.D.
  • 年度 2015
  • 页码 187 p.
  • 总页数 187
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号